Compare Wahed FTSE USA Shariah ETF (HLAL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Tango Therapeutics Inc. — how do they compare? Wahed FTSE USA Shariah ETF trades at $74.1 (market cap $997.79M), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is far larger — about 3.7× Wahed FTSE USA Shariah ETF's market cap, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Wahed FTSE USA Shariah ETF for 67 Days and Tango Therapeutics Inc. for 0 Days on average.
| HLAL | TNGX | |
|---|---|---|
Market Cap | $997.79M | $3.74B |
Volume | 65,395 | 3,438,781 |
Sector | Sector/Thematic | Health |
52-Week High | $76.54 | $32.90 |
52-Week Low | $57.46 | $7.50 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $75.90, showing modest daily gains of 0.13% with a bullish technical outlook supported by moving averages. The stock faces resistance near $77-78 while finding support at $75-74 levels. Key technical indicators show mixed signals with RSI suggesting potential overbought conditions on shorter timeframes.
Investment outlook remains data-dependent given limited fundamental information availability. The technical setup suggests near-term upside potential if resistance levels are breached, though momentum indicators warrant caution. Investors should await upcoming financial disclosures for clearer fundamental assessment.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
